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Abstract
Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option for people with previously 
refractory B cell malignancies and are under development for a wide range of other tumours. However, neurological toxic-
ity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term 
immune effector cell-associated neurotoxicity syndrome (ICANS) has been used to describe and grade neurotoxicity seen 
after CAR-T cells and other similar therapies. ICANS following CAR-T therapy is usually self-limiting but can necessitate 
admission to the intensive care unit and is rarely fatal. As CAR-T therapies enter routine clinical practice, it is important for 
neurologists to be aware of the nature of neurological complications. Here, we summarise the clinical manifestations, mecha-
nisms, investigations and recommended treatment of CAR-T-related neurotoxicity, focusing on the licensed CD19 products.
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Introduction
The development of chimeric antigen receptor (CAR)-
expressing T cells represents a major advance for the 
treatment of haematological malignancy. Autologous or 
allogeneic T cells are leukapheresed and genetically modi-
fied ex vivo by viral transduction to generate an advanced 
therapy medicinal product (ATMP; Fig. 1). The T cells are 
modified to express a CAR, which features an antigen detect-
ing single-chain variable fragment, expressed on the cell sur-
face acting as the target binding domain. This extracellular 
antigen recognition moiety is fused via a transmembrane 
domain to an intracellular co-stimulatory domain (such as 
CD28 and 4-1BB) and a CD3-zeta activation domain. The 
transduced anti-tumour CAR-T cells are expanded ex vivo 
and infused into the patient, following lymphocyte deplet-
ing chemotherapy to facilitate CAR-T cell expansion in the 
host. The intrinsic activation mechanism within CAR-T cells 
allows them to become fully activated and acquire the full 
repertoire of effector functions on encountering tumour anti-
gen, without the need for major histocompatibility complex-
epitope presentation.
Autologous anti-CD19 CAR-T cells are the most widely 
studied. Clinical trials demonstrating response rates of 
50–80% in previously refractory B cell lymphomas [1, 2], 
and 65–90% in acute lymphoblastic leukaemia (ALL) [3], 
have led to the licensing of two CAR-T products. Tisagen-
lecleucel (Kymriah) is licensed by the European Medicines 
Agency for treatment of refractory B cell ALL in children 
and young adults up to 25 years of age and refractory dif-
fuse large B cell lymphoma (DLBCL) in adults. Axicabta-
gene ciloleucel (Yescarta) is licensed for the treatment of 
adults with refractory DLBCL or primary mediastinal large 
B cell lymphoma. Approval for a third product, lisocabta-
gene maraleucel (Lisocel or JCAR017), is expected soon 
[4]. The existing anti-CD19 CAR-T therapies are currently 
being investigated for use earlier in the treatment pathway, 
and for expanded indications. New CAR-T therapies are also 
being developed for solid tumours including gastrointestinal 
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cancer, skin cancer, genitourinary, breast, gynaecological, 
lung, multiple myeloma, brain tumours and sarcoma [5, 6].
Despite their impressive efficacy, anti-CD19 CAR-T thera-
pies are associated with high rates of toxicities, the most com-
mon being cytokine release syndrome (CRS) and neurotoxic-
ity (Fig. 2). CRS is a multi-system clinical syndrome with 
manifestations ranging from mild flu-like symptoms to life-
threatening inflammatory response. Features can include fever, 
tachycardia, hypotension, hypoxia, and organ dysfunction. 
CRS arises due to profound and generalised immune system 
activation, associated with supra-physiological levels of circu-
lating cytokines. Symptomatic management with antipyretics, 
fluids, oxygen therapy and organ support, including advanced 
airway support where necessary, form the basis of supportive 
care. Tocilizumab, an interleukin-6 (IL-6) receptor blocking 
monoclonal antibody, is used for more severe cases and often 
results in rapid and complete resolution of CRS [7]. Tocili-
zumab offers an opportune mechanism of action by blocking 
a key driver for CRS, but with little impact on T cell function.
Neurotoxicity following CAR-T therapy is usually self-
limiting but can necessitate admission to the intensive care 
unit (ICU) and is rarely fatal. As CAR-T therapies enter routine 
clinical practice, it is important for neurologists to be aware 
of the nature of neurological complications. Here, we sum-
marise the clinical manifestations, mechanisms, investigations 
and recommended treatment of CAR-T-related neurotoxicity, 
focusing on the licensed CD19 products.
Fig. 1  Schematic diagram illustrating the process of CAR T cell therapy  © 2017 Terese Winslow LLC, US Government has certain rights. Note 
for the editor: copyright has been granted for re-use of this image. I can supply the agreement
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Clinical features of neurotoxicity
A diverse range of clinical manifestations of neurotoxicity 
have been reported. This diversity may be partly explained 
by the varied nomenclature used to describe the hallmark 
feature of encephalopathy. Furthermore, there may be some 
variability in the presentation of neurotoxicity with different 
CAR products. However, many individuals with neurotoxic-
ity seem to demonstrate a stereotypic pattern and temporal 
evolution of symptoms [5, 8].
Common early clinical manifestations of neurotoxicity 
include tremor and mild problems with attention and expres-
sive language [8–11]. Tremor tends to be heightened physi-
ological tremor, but more disabling rest, postural or intention 
tremors have been described [8]. Dysgraphia and expressive 
dysphasia are common, especially difficulty naming [5, 12]. 
Other features of the mild encephalopathy include disorien-
tation to time and place, short-term memory dysfunction, 
apraxia, hallucinations and behaviour disturbance includ-
ing impulsivity, emotional lability or abulia [8, 13]. Visual 
symptoms are reported but tend to be mild and transient, 
often with migrainous characteristics [8, 10]. Lethargy and 
headache are frequent, but relatively non-specific, early 
symptoms [5, 9, 11]. Patients can be somnolent in the early 
stages but often there is preserved alertness [8, 11, 13].
The majority of cases of neurotoxicity are mild or mod-
erate [8]. Those who do progress to severe neurotoxicity, 
usually do so over hours to days, and follow a reverse pattern 
during recovery [5, 8]. Occasionally, neurotoxicity presents 
with rapid onset encephalopathy and features of cerebral 
oedema that rapidly proves fatal. This fulminant presenta-
tion, in the absence of antecedent clinical signs, may have 
a distinct pathophysiology from the more characteristic, 
reversible neurotoxicity [5, 13]. As neurotoxicity evolves 
to become more severe, expressive language function often 
deteriorates, including impaired naming, paraphasic errors, 
verbal perseveration or, in extreme cases, global aphasia or 
mutism [8, 13]. Myoclonus, ataxia, meningism and auto-
nomic instability may become apparent [5, 8, 13]. There 
may be mild somnolence or a more depressed level of con-
sciousness requiring ICU support [11]. Paradoxically, some 
individuals may manifest with an agitated delirium [8]. 
Subclinical electrographic or clinical seizures often follow 
the development of severe expressive dysphasia. Seizures 
Fig. 2  Timing of complications following CAR T cell infusion (from [47], with kind permission Copyright© 2020, Springer Nature)
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tend to be generalised tonic–clonic seizures, with evidence 
of focal onset in some cases [11, 13]. Some authors con-
sider seizures to be more likely in children and in those with 
radiographic evidence of cerebral oedema [10]. Seizures can 
be prolonged despite early administration of seizure rescue 
medications [14].
Focal weakness of the limbs or face, or sudden onset 
dysphasia, is seen in a significant minority of cases [8–11, 
13]. Some cases mimic stroke or seizure-like events, in the 
absence of MRI or EEG correlates [13]. Pre-existing vascu-
lar risk factors appear to be more common in this group and 
deficits are typically transient [8].
Examination of people with severe neurotoxicity can 
reveal frontal release signs such as palmomental, snout, or 
grasp reflexes. There may be increased tone, evidence of 
focal weakness or facial automatisms [8, 13].
Timing and relationship with CRS
Neurotoxicity can occur in absence of CRS [9], but severe 
neurotoxicity almost always occurs in people who experi-
enced preceding CRS [8, 10, 13]. Some authors believe neu-
rotoxicity has a biphasic presentation; the first phase coin-
ciding with CRS symptoms, tending to be milder and shorter 
duration, and a second phase occurring after the fever and 
other CRS symptoms subside, and tending to be more severe 
and protracted [12]. Cases of delayed neurotoxicity have 
been reported, with seizures or confusion occurring 3 or 
4 weeks after CAR-T cell therapy [12].
On average, the symptoms of neurotoxicity start later than 
those of CRS (Fig. 2) [9, 13]. Median time from CAR-T 
infusion to onset of neurotoxicity is reported to be 4–6 days 
[2, 8, 11, 13, 15]. Peak neurotoxicity is reported to occur 
around day 7–9 with a median duration of 5–13 days [8, 
11–13, 15].
The majority of cases of neurotoxicity resolve within 
3–8 weeks [16]. However, up to 10% of cases of neuro-
toxicity were unresolved at the final follow-up visit of the 
seminal clinical trials (median follow-up 3–28 months) [2, 
16–18]. Detailed long-term follow-up data are so far scarce. 
There have been anecdotal reports of long-term sequelae 
of neurotoxicity including epilepsy [11], and mild memory 
impairment [15]. Twelve-month follow-up data on 86 peo-
ple who received CD19 CAR-T cells for relapsed/refractory 
ALL, NHL, or CLL during phase I/II clinical trials found 
no neurological or psychiatric adverse events persisting 
beyond 90 days. However, there has been a recent report of 
an unusually delayed and recurrent case of ICANS following 
axicabtagene ciloleucel administration for DLBCL. In the 
76-year-old woman, ICANS occurred at day 6 post CAR-T 
infusion, responding initially to dexamethasone but recur-
ring after steroid taper, and recurring again almost 6 months 
post infusion, proving steroid refractory on the last occasion 
[19].
Definition and grading of CAR‑T‑associated 
neurotoxicity
When CAR-T therapies were developed, the widely 
used Common Terminology Criteria for Adverse Events 
(CTCAE) scoring system were used to grade neurotoxicity 
[20]. The generic CTCAE system assigns a grade between 
1 and 5 for mild, moderate, severe, life-threatening or fatal 
events. However, the CTCAE system includes several 
terms relevant to encephalopathy, which overlap. In 2018, 
the CAR-T cell-therapy-associated TOXicity (CARTOX) 
working group published recommendations for the grad-
ing of neurotoxicity [12], which was refined in 2019 by the 
American Society for Transplantation and Cellular Therapy 
(ASTCT) [5]. The ASTCT group coined the term immune 
effector cell-associated neurotoxicity syndrome (ICANS). 
The refined definition and grading system were aimed at 
including a wide range of clinical features, but omitting 
those with poor specificity or confounding causes, and 
to acknowledge that similar syndromes can be seen with 
different immune treatments. The ICANS grading system 
remains in widespread use (Table 1) [5], assigning a grade 
between 1 and 4, according to scores in five domains. First, 
the Immune Effector Cell-Associated Encephalopathy (ICE) 
is used to assess cognition. The ICE is a 10-point score that 
draws upon components of the Mini-Mental State Examina-
tion (MMSE) to assess orientation, naming, ability to fol-
low commands, handwriting and attention. The other four 
domains in the ICANS grading system are: level of con-
sciousness, seizures, motor findings and evidence of elevated 
intracranial pressure. A separate but similar grading scale 
was developed for children < 12 years [5].
Incidence and severity of neurotoxicity
Despite recent changes to the definition and grading of neu-
rotoxicity, published clinical trial and cohort data for the 
licensed CD19 CAR-T therapies used the CTCAE grading 
system. Some trials chose to count any seizure as grade 3 
neurotoxicity [2, 21], and one trial counted any motor weak-
ness as grade 4 neurotoxicity [2]. Interestingly, the CTCAE 
system seems to over-report neurotoxicity; re-analysis of 
safety data graded using the ICANS system resulted in 
downgrading over 50% of neurotoxicity events in one trial 
to grade zero [22].
During clinical trials of the licensed CD19 CAR-T 
products, the overall incidence of neurotoxicity using the 
CTCAE grading ranged from 21 to 64%, and incidence of 
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severe neurotoxicity was 5–50% [13, 23–32]. In a cohort of 
43 children and young adults with ALL, neurotoxicity was 
observed in 44% cases (21% severe) [14]. Whereas a further 
study of 100 adults with a range of (predominantly B cell) 
malignancies, neurotoxicity was reported in 48% cases (20% 
severe) [8].
Risk factors for ICANS
The wide variation in the reported incidence of neurotoxicity 
may be explained by the factors relating to the underlying 
disease, prior treatments, the pre-morbid health of the recipi-
ent, as well as the features relating to the CAR-T construct 
and manufacture.
Higher pre-treatment B cell tumour burden appears to 
predict higher likelihood of neurotoxicity following CD19 
CAR-T [2, 9, 13, 16, 33]. Rates of ICANS may vary accord-
ing to the type of B cell malignancy [11]. Higher CAR-T 
dose, and certain conditioning regimens may predict the 
risk of subsequent neurotoxicity [11]. In particular, use of 
fludarabine for lymphodepletion may predispose to ICANS, 
possibly as a result of greater in vivo CAR-T cell expan-
sion, or as a direct toxic effect of fludarabine on the brain 
or endothelium [11, 18]. ICANS is also predicted by the 
presence of earlier and higher peaks in serum CRP, serum 
cytokines, and symptoms of CRS including high fever 
following CD19 CAR-T treatment [2, 8, 11, 13, 14]. The 
presence of pre-morbid neurological disease or MRI brain 
changes also appears to increase the risk of ICANS, which 
has led to a cautious use of CAR-T therapy in patients with 
known CNS involvement of leukaemia or lymphoma [11, 
14].
Features of the CAR design are also likely to be rele-
vant in predicting the incidence of toxicity [10, 34, 35]. In 
particular, the use of a humanised or murine single-chain 
variable fragment (scFv), the use of hinge and transmem-
brane domains derived from either the CD28 or the CD8α 
molecule, and the use of CD28 co-stimulatory moieties have 
all been postulated to be relevant to the likelihood of ICANS 
[35, 36]. The currently licensed anti-CD19 CARs have scFvs 
derived from murine antibodies. In a recent phase 1 trial of 
a new CD19 CAR-T therapy, featuring a fully humanised 
scFv and a hinge and transmembrane domain derived from 
CD8α, the anti-lymphoma effect appeared to rival licensed 
CD19 CAR-T products, but ICANS was only observed in 1 
out of 20 (5%) recipients [37].
The CAR manufacturing approach may also be relevant. 
A trial using a CAR construct, that was already in exist-
ence (CD19 CAR with a CD28 co-stimulatory domain) but 
using a different manufacturing approach, was closed early 
because of a high incidence of fatal ICANS [38].
Overall, the rates of ICANS appear lower for non-CD19 
CAR-T cells-targeting hematologic malignancies, and neuro-
toxicity has not been reported in solid tumour CAR-T thera-
pies (with exception of brain tumour trials) [10]. It seems 
likely that the higher risk of ICANS after CD19-targeted 
therapies reflects their capacity for robust T cell activa-
tion compared to T cell therapies targeting other antigens 
expressed on different tumours, possibly related to the higher 
accessibility to CD19 tumour cells, or their level of antigen 
expression [11].
Potential mechanism of neurotoxicity
The pathophysiology of ICANS following CAR-T therapy 
is not fully understood, although several possible mecha-
nisms have been proposed. The heterogeneity in clinical 
presentations, imaging and laboratory features of ICANS 
make it plausible that different mechanisms are at play [10]. 
Furthermore, confounding contributors of organ dysfunc-
tion, hypoxaemia and infection may lead to a wider range of 
presentations [12].
The finding that high tumour burden, high levels of 
CAR-T expansion and severe CRS all predict subsequent 
ICANS, supports the concept that cytokine release is likely 
Table 1  Immune Effector Cell-
Associated Encephalopathy 
(ICE) grading score of ICANS 
(adapted from [5], with kind 
permission, © 2018 American 
Society for Blood and Marrow 
Transplantation)
ICE score
 Orientation: orientation to year, month, city, hospital: 4 points
 Naming: ability to name three objects (e.g. point to clock, pen, button): 3 points
 Following commands: ability to follow simple commands (e.g. “Show me 2 fingers” or “Close your eyes 
and stick out your tongue”): 1 point
 Writing: ability to write a standard sentence (e.g. “Our national bird is the bald eagle”): 1 point
 Attention: ability to count backwards from 100 by 10: 1 point
Scoring:
 10, no impairment
 7–9, grade 1 ICANS
 3–6, grade 2 ICANS
 0–2, grade 3 ICANS
 0 due to patient unarousable and unable to perform ICE assessment, grade 4 ICANS
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to be relevant. Indeed, several groups have shown blood 
cytokine levels to be higher in people with ICANS versus 
those without. Numerous groups have also demonstrated 
high cerebrospinal fluid (CSF) levels of cytokines in people 
with ICANS [11, 13, 14, 39], but uncertainty remains over 
whether cytokines are peripherally produced and trafficked 
into the CNS, or centrally produced. Evidence of endothelial 
activation and blood brain barrier (BBB) disruption in peo-
ple with ICANS is well established, raising the possibility 
that peripheral cytokines cross into the CNS [11]. However, 
CAR-T cells have also been demonstrated to gain access to 
the CNS, and are present in higher numbers in the CSF of 
those with ICANS [40]. Some groups have reported dispro-
portionately high levels of cytokines in CSF (versus blood) 
in severe ICANS, supporting at least some CNS cytokine 
production [13, 39].
Cytokine profiling of the blood and CSF in the context 
of ICANS has shown a range of candidate molecules. The 
majority report high IL-6, the cytokine most strongly asso-
ciated with CRS [8, 10, 13, 14, 39]. One group observed 
that the rate of rise in serum cytokine concentration, as well 
as the peak concentration was predictive of ICANS [11]. 
Severe ICANS is also associated with elevated levels of a 
range of other cytokine or chemokines including IL-1Ra, 
IL-2Ra, IL-1, IL2, IL-8, IL-10, IL-15, IFN-gamma, CCL-2, 
granzyme B, GM-CSF and VEGF [2, 14, 39]. This suggests 
that cells other than T cells, including endothelial cells and 
monocytes, may be implicated [10, 41]. The role of mac-
rophage activation in ICANS is further supported by mark-
edly elevated serum ferritin in some cases, reminiscent of 
macrophage activation syndrome and hemophagocytic lym-
phohistiocytosis [42]. Neuropathologic studies at autopsy 
after fatal ICANS have demonstrated a widespread inflam-
matory process in some cases, involving dense macrophage 
infiltration of white matter, numerous microglial cells, and 
a moderate CD8+ T cell infiltrate [18, 39], and CAR-T cells 
within the brain tissue [11, 39]. In other cases, evidence of 
oedema, astrocytic damage, activated microglia and BBB 
dysfunction have been present in the absence of a lympho-
cytic infiltrate [8, 10, 43].
The post mortem and CSF findings demonstrating lym-
phocytosis raise the possibility that ICANS arises as a 
result of a T cell encephalitis. Post mortem cases have not 
shown any evidence of herpes simplex virus 1 or 2, cyto-
megalovirus, varicella zoster virus, JC virus, adenovirus, or 
Epstein–Barr virus [18]. Reactivity of CAR-T cells with a 
non-target antigen in the brain would be a plausible mecha-
nism of encephalitis, although it remains unclear whether 
CNS involvement of leukaemia predicts a higher risk of 
ICANS [9]. Furthermore, the low incidence of brain paren-
chymal abnormality on MRI in people with ICANS does not 
necessarily align with the presence of encephalitis.
It is possible that endothelial activation and BBB perme-
ability is of fundamental importance in ICANS, allowing 
cytokines and CAR-T cells pass into the CNS [11]. It has 
been proposed that a tendency towards endothelial activation 
may even pre-date CAR-T infusion in those who go on to 
develop ICANS [11], implying certain individuals may be at 
risk. In susceptible individuals, a more permeable BBB may 
expose brain vascular pericytes to high concentrations of cir-
culating cytokines, inducing further endothelium-activation 
[11]. This process is somewhat analogous to eclampsia or 
posterior reversible encephalopathy syndrome (PRES) [8]. 
Once cytokines have access to the CNS they may exert their 
effects in the absence of a centrally directed inflammatory 
response. For instance, one group found high levels of qui-
nolinic acid and glutamate, agonists to N-methyl-d-aspar-
tate (NMDA) receptor, in CSF during ICANS, suggesting 
that endogenous excitatory agonists may be involved [13]. 
Raised CSF levels of GFAP, S100b during ICANS also 
raise the possibility that astrocytic injury may contribute to 
osmotic dysregulation and cerebral oedema.[14]
Investigation of neurotoxicity
In a patient with suspected ICANS, investigations are mostly 
aimed at ruling out mimics or contributory factors including 
infection, cerebral involvement of B cell malignancy, drug 
toxicity, metabolic derangement or organ dysfunction. CT 
and MR imaging of the brain is normal in most cases of mild 
ICANS and in many individuals with more severe ICANS 
[8, 10, 13]. CT imaging is often more practical in an unwell 
patient and is useful in excluding pathology such as cerebral 
haemorrhage, infarct and oedema. Where MRI is abnormal, 
various patterns have been observed. In some cases, there are 
T2/FLAIR hyperintensities involving the bilateral thalami 
and brainstem, or cerebral white matter, without diffusion 
restriction, which resolve on subsequent imaging performed 
after neurologic symptom resolution [13, 14]. Another MRI 
pattern observed is transient T2 hyperintense lesions within 
the splenium of the corpus callosum or in a gyral pattern that 
not only restricts on diffusion imaging but also resolves on 
follow-up imaging [10, 13]. Two cases of primary cerebellar 
involvement have been reported, although one had previous 
radiation-related cerebellar injury [14]. A small number of 
cases of ischaemic stroke and subarachnoid haemorrhage 
have been reported, as well as a single case of bilateral intra-
labyrinthine cochlear haemorrhage [8]. Where MR imag-
ing has been normal, occasionally focal neurological deficits 
have been associated with FDG-PET hypometabolism, or 
elevated velocities on transcranial Doppler ultrasound [8].
Electroencephalogram (EEG) most commonly shows 
frontal intermittent rhythmic delta activity, loss of posterior 
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dominant rhythm and diffuse or focal slowing with or with-
out triphasic waves, in keeping with an encephalopathic state 
[8, 10, 12, 13]. Most often, EEG seizure activity coincides 
with clinical seizure activity, but non-convulsive status may 
occur in as many as 10% of cases [10, 12, 13]. The role of 
continuous EEG monitoring remains uncertain. Real-time 
monitoring may be available on some, but not all ICUs. 
However, real-time interpretation of continuous EEG pre-
sents a challenge in many departments. The role of continu-
ous EEG may remain limited to the monitoring of seizure 
control of those with proven status epilepticus, although 
further evidence may support a wider role in people with 
ICANS.
Lumbar puncture may be challenging in an encephalo-
pathic patient and CSF findings diagnostic of ICANS are 
lacking. While CSF can show evidence of BBB permeabil-
ity and/or lymphocytic pleocytosis in an individual with 
ICANS, both are non-specific and neither correlate with neu-
rotoxicity severity [8, 13]. CSF examination is mainly useful 
to rule out concurrent infection, using directed antimicrobial 
testing, and to rule out CNS lymphoma or leukaemia. Serum 
and CSF biomarkers diagnostic of ICANS are highly sought 
after but none are yet validated for use in clinical practice.
Management of neurotoxicity
Supportive management of neurological complications 
of CAR-T therapy requires close liaison and partnership 
between haematology, neurology and critical care col-
leagues. Regular morbidity and mortality review of all cases 
where neurological complications have occurred is valuable 
to build local expertise. Systematic monitoring of patients 
following CAR-T cell infusion should be performed on a 
haematology ward. Clear care algorithms should be in place 
with appropriate triggers for referral should complications 
arise, that are reviewed regularly. Vigilant management of 
infection or metabolic derangement is important (Fig. 3). 
Neurological assessment is recommended prior to CAR-T 
therapy and daily during the first 10 days following CAR-T 
cell infusion [44]. The patient may be transitioned to man-
agement through an ambulatory care setting following day 
10 providing there are no active toxicities. Such patients are 
recommended to remain within 1 h of the treatment centre 
for the first 28 days after CAR-T treatment, with continuous 
presence of a caregiver who is trained in the recognition of 
symptoms including ICANS [44]. The ICE score (Table 1) 
and ICANS grading system (Table 2) are the most widely 
used tools to detect and monitor ICANS, but in our experi-
ence may lack sensitivity in early cases.
Corticosteroids are the mainstay of treatment for ICANS. 
The lymphotoxic action of corticosteroids poses a risk of 
reducing the anti-malignancy effect of CD19 CAR-T cells 
[9, 45], but the efficacy in reversing ICANS makes them 
appropriate therapy for moderate or severe ICANS. Where 
conscious level is depressed, dexamethasone 10 mg qds for 
1–3 days is recommended. In grade 4 ICANS where patients 
may be unrousable, have status epilepticus or imaging fea-
tures of cerebral oedema, then methylprednisolone 1000 mg 
is recommended [44, 46].
Tocilizumab is a humanised monoclonal antibody that 
binds to both soluble and membrane bound IL-6 receptor 
(IL-6R). It was developed to treat rheumatological disorders, 
but can be used for ICANS, although evidence suggests the 
benefit is most when ICANS occurs early and/or in com-
bination with CRS [10, 12]. This may relate to increased 
permeability of the BBB at an early stage, facilitating 
greater access for tocilizumab into the CNS [12]. In cases 
of isolated ICANS, tocilizumab may not benefit, and there 
have been some concerns that it could in fact paradoxically 
increase CNS IL-6 levels, potentially aggravating ICANS 
[14, 16], This has led some treatment algorithms to recom-
mend avoiding use of tocilizumab even when it coincides 
with CRS [46]. Siltuximab, which directly binds IL-6, may 
be more beneficial in cases of isolated ICANS, but it has 
mainly been trialled where tocilizumab has failed, which 
may be too late [10]. Preclinical work suggests future target-
ing of IL-1, using therapies such as anakinra (monoclonal 
antibody to IL-1R) may benefit ICANS, although clinical 
evidence remains anecdotal [16, 41, 46]. Even direct target-
ing of monocytes, rather than eliminating their downstream 
targets may warrant consideration [16].
Anti-seizure medications were introduced prophylac-
tically as ICANS emerged during early trials. However, 
opinion remains divided about the benefit of prophylactic 
use of anti-epileptics as they have not been clearly demon-
strated to reduce seizure complications [10, 13, 14]. Treat-
ment of emergent seizures with standard benzodiazepine and 
antiepileptic drug titration appears effective in most cases 
although refractory or prolonged seizures can occur [13, 
14]. Levetiracetam appears the favoured choice of antiepi-
leptic in people with ICANS, likely due to its low incidence 
of drug–drug interactions, low risk of cardiotoxicity, and 
favourable safety profile in people with hepatic dysfunction 
[10, 12].
Patients with grade > / = 3 ICANS should be managed 
in the ICU setting, including airway support where there 
is reduced consciousness. In severe cases of ICANS, with 
features of cerebral oedema, supportive measures to man-
age raised intracranial pressure (ICP), including use of ICP 
monitors, targeting cerebral perfusion pressure and hyperos-
molar therapy are advocated by some groups.[10, 44]
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Other neurological complications of CAR‑T
Aside from ICANS, recipients of CAR-T cells, there have 
also been case reports of PRES [47], and progressive mul-
tifocal leukoencephalopathy after CAR-T therapy [48]. 
Intracranial haemorrhage has also been rarely observed 
[8, 11]. Unravelling causation in these cases is challenging 
given the contributions of underlying malignancy and prior 
conditioning therapies. The incidence of infection within 
the first 28 days of CAR-T therapy was almost 25% in one 
case series of 133 patients, although the rate and nature of 
infections seem to be  in line with other salvage chemoim-
munotherapy approaches for haematological malignancy 
[49]. Infections were commonly bacterial or viral respira-
tory illness, but also included the finding of EBV or CMV 
in the CSF, and occasionally disseminated fungal infection. 
All patients commencing CAR-T therapy should routinely 
receive prophylaxis for herpes infection and prophylaxis for 
Pneumocystis pneumonia, but anti-bacterial and systemic 
anti-fungal prophylaxis are not routinely recommended [44].
Conclusions
CD19 CAR-T therapies now provide an effective treatment 
for previously refractory B cell malignancies. However, 
ICANS is a common complication, which can be serious, 
and rarely fatal. Regular evaluation of CAR-T recipients 
is required during the first 14 days using validated scoring 
tools. Treatment of ICANS is largely supportive, including 
vigilant exclusion of infection and adequate treatment of 
seizures. Corticosteroids and intensive care support are the 
mainstay of treatment for higher grades of ICANS. Novel 
therapies such as siltuximab and anakinra warrant further 
study and data on long-term neurological outcomes follow-
ing CAR-T are awaited.
Fig. 3  Best practice recommendations for the management of ICANS 
following CAR T cell therapy according to the European Society for 
Blood and Marrow Transplantation (EBMT) and the Joint Accredita-
tion Committee of ISCT and EBMT (JACIE). From [45], with kind 
permission Copyright© 2020 Ferrata Storti Foundation
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